FDA encourages opioid prescribers to pursue training

FDA encourages opioid prescribers to pursue training
Prescribers of extended-release/long-acting opioid analgesics are encouraged to participate in continuing medical education provided by manufacturers of these analgesics, according to an open letter published March 1 by the U.S. Food and Drug Administration.

(HealthDay)—Prescribers of extended-release/long-acting (ER/LA) opioid analgesics are encouraged to participate in continuing medical education (CME) provided by manufacturers of these analgesics, according to an open letter published March 1 by the U.S. Food and Drug Administration.

Delivery of CME is part of the risk evaluation and mitigation strategy (REMS) approved by the FDA in July 2012, and is due to begin in 2013. Using input from stakeholders, CME activities have been developed in accordance with an FDA blueprint, which sets out the core messages to be delivered.

According to the letter, prescribers of ER/LA opioids are encouraged to take advantage of opioid-specific training funded by manufacturers, with the aim of combating misuse and abuse of these medications. The American Academy of Family Practitioners (AAFP) will receive grant funding to support CME addressing the issues included in the blueprint, and anticipates that CME programs will be available this summer. The FDA hopes that 60 percent of the 320,000 prescribers of ER/LA opioids in 2011 will participate in REMS CME during the next three years.

"The goal is that voluntary participation in this CME will help to address the growing problem of prescription drug abuse and misuse," said Kathy Marian, M.Ed., the AAFP manager of CME standards and outcomes, said in a statement. "The REMS introduces new to reduce risks and improve safe use of ER/LA opioids while continuing to provide access to these medications for patients in pain."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

FDA: Draft guidance issued on abuse-deterrent opioids

Jan 10, 2013

(HealthDay)—The U.S. Food and Drug Administration has issued a draft guidance document to assist the pharmaceutical industry in developing new formulations of opioid drugs with abuse-deterrent properties.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments